share_log

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Given Average Recommendation of "Hold" by Brokerages

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Given Average Recommendation of "Hold" by Brokerages

瑞格爾製藥股份有限公司（NASDAQ：RIZL）給出經紀公司對「持有」的平均建議
Defense World ·  2022/09/22 02:41

Shares of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL – Get Rating) have been given a consensus recommendation of "Hold" by the nine research firms that are covering the stock, Marketbeat.com reports. Five analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $3.96.

瑞格爾製藥股份有限公司 (NASDAQ: RIZL — 獲得評級) 已經給予的共識建議「持有」由九家研究公司正在覆蓋股票, MarketBeat.com 報告.五位分析師對該股票進行了保持評級，其中一位分析師為該公司分配了買入評級。在過去一年發布了股票報告的分析師中，平均 1 年價格目標為 3.96 美元。

Several equities analysts have recently weighed in on the stock. Piper Sandler raised their price target on shares of Rigel Pharmaceuticals from $1.00 to $2.00 and gave the stock a "neutral" rating in a research note on Tuesday, August 16th. StockNews.com cut shares of Rigel Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Tuesday, September 13th. Cantor Fitzgerald cut shares of Rigel Pharmaceuticals from an "overweight" rating to a "neutral" rating and decreased their target price for the company from $6.00 to $1.00 in a research note on Wednesday, June 8th. HC Wainwright raised their target price on shares of Rigel Pharmaceuticals from $7.00 to $15.00 and gave the company a "buy" rating in a research note on Thursday, August 18th. Finally, B. Riley decreased their target price on shares of Rigel Pharmaceuticals from $4.00 to $1.25 and set a "neutral" rating for the company in a research note on Thursday, June 9th.

幾名股票分析師最近對股票進行了權衡。派珀·桑德勒將瑞格爾藥品股票的價格目標從 1.00 美元提高到 2.00 美元，並在 8 月 16 日（週二）的一項研究報告中給予該股「中性」評級。Stocknews.com 在 9 月 13 日（星期二）的研究報告中將 Rigel 藥品的股票從「買入」評級降至「持有」評級。坎特·菲茨杰拉德（Cantor Fitzgerald）將 Rigel 藥品的股票從「超重」評級降至「中性」評級，並在 6 月 8 日（星期三）的研究報告中將其目標價格從 6.00 美元降至 1.00 美元。溫賴特（HC Wainwright）將瑞格爾製藥股份的目標價從 7.00 美元提高至 15.00 美元，並在 8 月 18 日（星期四）的一份研究報告中給予該公司「買入」評級。最後，萊利在 6 月 9 日（星期四）的一份研究報告中，Rigel 藥品的股票目標價格從 4.00 美元降至 1.25 美元，並為該公司設定了「中性」評級。

Get
取得
Rigel Pharmaceuticals
利格尔制药
alerts:
警報：

Rigel Pharmaceuticals Stock Performance

利格爾藥品股票表現

Shares of RIGL stock opened at $1.21 on Thursday. The company has a debt-to-equity ratio of 4.39, a quick ratio of 2.08 and a current ratio of 2.19. The company has a market capitalization of $209.13 million, a P/E ratio of -2.47 and a beta of 1.54. The company's 50 day moving average price is $1.39 and its two-hundred day moving average price is $1.91. Rigel Pharmaceuticals has a 52 week low of $0.64 and a 52 week high of $3.91.

REGL 股票的股票在周四 1.21 美元開盤。該公司的債務與權益比率為 4.39，快速比率為 2.08，流動比率為 2.19。該公司的市值為 20913 萬美元，市盈率為 -2.47，測試版為 1.54。該公司的 50 天移動平均價格為 1.39 美元，其 200 天移動平均價格為 1.91 美元。蕾格爾製藥有 52 周低點 0.64 美元，52 周高點為 3.91 美元。

Institutional Investors Weigh In On Rigel Pharmaceuticals

機構投資者權衡 Rigel 製藥

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Goldman Sachs Group Inc. raised its stake in Rigel Pharmaceuticals by 209.2% in the second quarter. Goldman Sachs Group Inc. now owns 1,937,924 shares of the biotechnology company's stock valued at $2,190,000 after purchasing an additional 1,311,254 shares in the last quarter. Woodline Partners LP raised its stake in Rigel Pharmaceuticals by 4.6% during the second quarter. Woodline Partners LP now owns 861,305 shares of the biotechnology company's stock worth $973,000 after acquiring an additional 37,641 shares in the last quarter. Price T Rowe Associates Inc. MD raised its stake in Rigel Pharmaceuticals by 102.5% during the second quarter. Price T Rowe Associates Inc. MD now owns 168,302 shares of the biotechnology company's stock worth $190,000 after acquiring an additional 85,200 shares in the last quarter. State Street Corp raised its stake in Rigel Pharmaceuticals by 218.2% during the second quarter. State Street Corp now owns 23,945,568 shares of the biotechnology company's stock worth $27,058,000 after acquiring an additional 16,421,362 shares in the last quarter. Finally, Cubist Systematic Strategies LLC raised its stake in Rigel Pharmaceuticals by 308.2% during the second quarter. Cubist Systematic Strategies LLC now owns 74,675 shares of the biotechnology company's stock worth $84,000 after acquiring an additional 56,380 shares in the last quarter. Institutional investors and hedge funds own 80.94% of the company's stock.
一些對沖基金和其他機構投資者最近修改了他們對該公司的持有。高盛集團公司在第二季度通過 209.2％ 提高了 Rigel 製藥的股份。高盛集團在上一季度額外購買 1,311,254 股股後，現擁有該生物技術公司股票的 1,937,924 股，價值為 2,190,000 美元。伍德林合作夥伴 LP 在第二季度提高了在蕾格爾製藥的股份 4.6%.在上個季度額外收購 37,641 股後，伍德林合作夥伴 LP 現在擁有該生物技術公司股票的 861,305 股價值 973,000 美元。價格 T 羅威聯營公司 MD 在第二季度上調了 Rigel 製藥的股份 102.5%.價格 T 羅威聯營公司. 馬里蘭州現在擁有 168,302 股價值 $190,000 在上個季度獲得了額外的 85,200 股股票後，生物技術公司的股票價值 $190,000.國街公司在第二季度提高了在利格爾製藥的股份 218.2%.國街公司現在擁有該生物技術公司股票的 23,945,568 股，價值 27,058,000 美元，在上個季度額外收購 16,421,362 股股票後。最後, 立體派系統策略有限責任公司提出了 Rigel 製藥的股份 308.2% 在第二季度.立體派系統策略有限責任公司現在擁有 74,675 股生物技術公司的股票價值 $84,000 在上個季度獲得額外的 56,380 股後。機構投資者和對沖基金擁有公司股票的 80.94%。

About Rigel Pharmaceuticals

關於利格爾製藥

(Get Rating)

(取得評分)

Rigel Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia.

瑞格爾製藥公司是一家生物技術公司，發現並開發用於治療血液學疾病，癌症和罕見免疫疾病的小分子藥物。該公司提供 Tavalisse，一種口服脾酪氨酸激酶抑製劑，用於治療慢性免疫性血小板減少症的成年患者。

Read More

閱讀更多

  • Get a free copy of the StockNews.com research report on Rigel Pharmaceuticals (RIGL)
  • The Worst May be Over for Target, But is the Stock Safe to Buy?
  • Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
  • Two Fun Stocks The Insiders Are Buying
  • Novavax Remains a Risk-On Stock in a Risk-Off Market
  • 3 Defensive Stocks With 60-Year Dividend Hike Streaks
  • 獲取有關瑞格爾製藥研究報告的免費副本
  • 最糟糕的情況可能已經結束了，但是股票可以安全購買嗎？
  • 這些液體天然氣股票是否準備好上行反彈？
  • 內部人士正在購買的兩個有趣的股票
  • Novavax 仍然是風險避險市場中的股票
  • 3 具有 60 年股息上調條紋的防禦性股票

Receive News & Ratings for Rigel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rigel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

接收利格爾藥品日報的新聞和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收 Rigel 製藥及相關公司的最新新聞和分析師評級的簡要每日摘要。

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論